JADPRO 2023
Patients with relapsed or refractory multiple myeloma sustained durable remissions after switching to biweekly teclistamab.
Dr. Coombs discussed the results from a survey of patients with myeloma and APPs who treat myeloma.
Elranatamab was effective and well-tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma.
Advertisement
Of the 200 APPs surveyed, 72% reported being “generally knowledgeable” about MM before seeing their first patient.
Getting the right care team, treatment, and testing are three steps to empower patients with MM.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.